DE69940735D1 - Biologisch abbaubare anordnungen zur kontrollierten freigabe eingeschlossener substanzen - Google Patents

Biologisch abbaubare anordnungen zur kontrollierten freigabe eingeschlossener substanzen

Info

Publication number
DE69940735D1
DE69940735D1 DE69940735T DE69940735T DE69940735D1 DE 69940735 D1 DE69940735 D1 DE 69940735D1 DE 69940735 T DE69940735 T DE 69940735T DE 69940735 T DE69940735 T DE 69940735T DE 69940735 D1 DE69940735 D1 DE 69940735D1
Authority
DE
Germany
Prior art keywords
physiologically active
active substance
biodegradable
release
arrangements
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69940735T
Other languages
English (en)
Inventor
Sankaram Bhima Mantripragada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pacira Pharmaceuticals Inc
Original Assignee
Pacira Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pacira Pharmaceuticals Inc filed Critical Pacira Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69940735D1 publication Critical patent/DE69940735D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y10T428/2985—Solid-walled microcapsule from synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
DE69940735T 1998-07-17 1999-07-16 Biologisch abbaubare anordnungen zur kontrollierten freigabe eingeschlossener substanzen Expired - Lifetime DE69940735D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9324398P 1998-07-17 1998-07-17
US10185598P 1998-09-25 1998-09-25
US12309799P 1999-03-05 1999-03-05
PCT/US1999/016239 WO2000003660A1 (en) 1998-07-17 1999-07-16 Biodegradable compositions for the controlled release of encapsulated substances

Publications (1)

Publication Number Publication Date
DE69940735D1 true DE69940735D1 (de) 2009-05-28

Family

ID=27377463

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69940735T Expired - Lifetime DE69940735D1 (de) 1998-07-17 1999-07-16 Biologisch abbaubare anordnungen zur kontrollierten freigabe eingeschlossener substanzen

Country Status (12)

Country Link
US (2) US6277413B1 (de)
EP (1) EP1098610B1 (de)
JP (2) JP2002520120A (de)
AT (1) ATE428371T1 (de)
AU (1) AU752225B2 (de)
CA (1) CA2338031C (de)
DE (1) DE69940735D1 (de)
ES (1) ES2325141T3 (de)
IL (2) IL140899A0 (de)
NO (1) NO20010264L (de)
NZ (1) NZ509186A (de)
WO (1) WO2000003660A1 (de)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU752802C (en) 1997-11-14 2006-04-13 Pacira Pharmaceuticals, Inc. Production of multivesicular liposomes
CA2276066A1 (en) * 1999-03-11 2000-09-11 Zycos Inc. Microparticles for delivery of nucleic acid
US7118921B1 (en) * 1999-06-24 2006-10-10 Mcmaster University Incorporation and applications of biomolecular interactions within a carrier
US7025980B1 (en) * 1999-09-14 2006-04-11 Tepha, Inc. Polyhydroxyalkanoate compositions for soft tissue repair, augmentation, and viscosupplementation
DE19949897A1 (de) 1999-10-15 2001-04-19 Rainer Rogasch Formkörper und Verfahren zu dessen Herstellung
US6734188B1 (en) * 1999-11-01 2004-05-11 John Rhodes Composition for treatment of constipation and irritable bowel syndrome
AU2001268159B2 (en) * 2000-06-02 2005-09-15 Eisai Inc. Delivery systems for bioactive agents
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
WO2002032398A2 (en) * 2000-10-16 2002-04-25 Massachusetts Institute Of Technology Lipid-protein-sugar particles for drug delivery
WO2002032396A2 (en) * 2000-10-16 2002-04-25 Massachusetts Institute Of Technology Lipid-protein-sugar particles for delivery of nucleic acids
US20030162733A1 (en) * 2000-11-27 2003-08-28 Haynes Joel R. Nucleic acid adjuvants
AUPR602501A0 (en) * 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release pharmaceutical composition
AUPR602401A0 (en) * 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release delivery system
JP3990880B2 (ja) * 2001-07-10 2007-10-17 キヤノン株式会社 ポリヒドロキシアルカノエート被覆リポソームの製造方法
ES2294147T5 (es) † 2001-07-27 2011-04-04 N.V. Nutricia Composiciones enterales para la prevención y/o tratamiento de la sepsis.
US6488952B1 (en) * 2001-08-28 2002-12-03 John P. Kennedy Semisolid therapeutic delivery system and combination semisolid, multiparticulate, therapeutic delivery system
KR100527408B1 (ko) * 2002-01-03 2005-11-09 한국과학기술원 카프로락톤과 락티드의 랜덤공중합체와 폴리에테르를이용한 생분해성 블록공중합체의 제조방법 및 이의 응용
WO2003062199A2 (en) * 2002-01-16 2003-07-31 Agency For Disease Diagnosis And Prevention Pace-a microspheres for delivery of antigens
JP4679822B2 (ja) * 2002-03-13 2011-05-11 ノバルティス アーゲー 医薬微粒子
US20040082521A1 (en) * 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
KR100573289B1 (ko) * 2002-07-20 2006-04-24 대화제약 주식회사 방광내 투여를 통한 방광암치료용 파클리탁셀 조성물 및그의 제조 방법
US6998074B1 (en) 2002-08-30 2006-02-14 Microfab Technologies, Inc. Method for forming polymer microspheres
US20040052836A1 (en) * 2002-09-13 2004-03-18 Li Luk Chiu Pharmaceutical compositions containing at least one stable liposphere having an improved shelf life
CA2501298A1 (en) * 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
CA2505520C (en) * 2002-11-06 2012-07-17 Azaya Therapeutics, Inc. Protein-stabilized liposomal formulations of pharmaceutical agents
US7736391B2 (en) 2003-02-06 2010-06-15 Tonaba Healthscience Ii, Llc Cosmetic and reconstructive prostheses with a microencapsulated biologically compatible rupture indicator for sustained release and methods of detecting compromise of a prosthesis
SE527505C2 (sv) * 2003-06-10 2006-03-28 Anna Imberg Komposita material och partiklar
US20060188573A1 (en) * 2003-06-10 2006-08-24 Anna Imberg Composite materials and particles
US20050009910A1 (en) * 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
US7943179B2 (en) 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
KR100663880B1 (ko) 2004-02-12 2007-01-03 한국과학기술연구원 고분자-지질 조성물, 구조체 및 이들의 제조방법
FR2868704B1 (fr) * 2004-04-07 2007-09-14 Ethypharm Sa Utilisation de lipides pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous cutanees ou intra-musculaires
US20080124400A1 (en) * 2004-06-24 2008-05-29 Angiotech International Ag Microparticles With High Loadings Of A Bioactive Agent
US7534449B2 (en) * 2004-07-01 2009-05-19 Yale University Targeted and high density drug loaded polymeric materials
AU2005325213B2 (en) 2004-08-04 2010-10-07 Evonik Corporation Methods for manufacturing delivery devices and devices thereof
JP5081622B2 (ja) * 2004-09-21 2012-11-28 山▲東緑▼叶制▲薬▼有限公司 ドーパミン受容体アゴニストを含む長時間作用する持続放出製剤、及びそれらの製造方法
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
US8252320B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
PL1814531T3 (pl) 2004-10-21 2010-11-30 Durect Corp Transdermalne systemy dostarczania
CA2587308A1 (en) * 2004-11-12 2006-05-18 Mayo Foundation For Medical Education And Research Photocrosslinkable poly(caprolactone fumarate)
EP1812481B1 (de) * 2004-11-18 2012-01-11 Mayo Foundation for Medical Education and Research Blockcopolymere aus polycaprolacton und poly (propylenfumarat)
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US8912247B2 (en) * 2005-04-29 2014-12-16 Mayo Foundation For Medical Education And Research Hydrophilic/hydrophobic polymer networks based on poly(caprolactone fumarate), poly(ethylene glycol fumarate), and copolymers thereof
US20070005213A1 (en) * 2005-06-30 2007-01-04 Hyundai Autonet Co., Ltd. Backward control for automobiles using telematics and method thereof
EP1926780B1 (de) 2005-09-22 2013-08-14 Medivas, LLC Bis-( -amino)-diol-diester-haltige poly(esteramid) und poly(esterurethan)-zusammensetzungen und verwendungsverfahren
EP1933881B1 (de) 2005-09-22 2019-03-13 Medivas, LLC Feste polymer-abgabezusammensetzungen und anwendungsverfahren dafür
ES2437581T3 (es) 2005-11-17 2014-01-13 Zogenix, Inc. Suministro de formulaciones viscosas por inyección sin aguja
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
US20070253994A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain
EP2044142A2 (de) 2006-06-29 2009-04-08 Medtronic, Inc. Poly(orthoester)polymere sowie herstellungs- und verwendungsverfahren dafür
CA2670821C (en) 2006-08-09 2012-05-15 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US20080138397A1 (en) * 2006-10-24 2008-06-12 Aradigm Corporation Processes for taste-masking of inhaled formulations
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
WO2008109347A2 (en) * 2007-03-02 2008-09-12 Yale University Methods for ex vivo administration of drugs to grafts using polymeric nanoparticles
MX2009011123A (es) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
WO2008135855A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008149192A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
EP2178944A1 (de) * 2007-07-24 2010-04-28 Medivas, LLC Biologisch abbaubare polymere genübertragungszusammensetzungen und anwendungsverfahren dafür
US8568445B2 (en) 2007-08-21 2013-10-29 St. Jude Medical Puerto Rico Llc Extra-vascular sealing device and method
US8333787B2 (en) * 2007-12-31 2012-12-18 St. Jude Medical Puerto Rico Llc Vascular closure device having a flowable sealing material
CA2713185A1 (en) * 2007-08-23 2009-02-26 Medivas, Llc Cationic alpha-amino acid-containing biodegradable polymer gene transfer compositions
EP2039352A1 (de) * 2007-09-18 2009-03-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Lipid-Nanokapseln mit wässrigem Kern zur Einkapselung hydrophiler und/oder lipophiler Moleküle
WO2009073216A1 (en) 2007-12-06 2009-06-11 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
WO2009073215A1 (en) 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
CA2709712C (en) 2007-12-20 2016-05-10 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles having a low residual solvent volume
US8840640B2 (en) * 2007-12-31 2014-09-23 St. Jude Medical Puerto Rico Llc Vascular closure device having an improved plug
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US8956642B2 (en) * 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
US8940315B2 (en) * 2008-04-18 2015-01-27 Medtronic, Inc. Benzodiazepine formulation in a polyorthoester carrier
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
EP3000462A1 (de) 2008-04-28 2016-03-30 Zogenix, Inc. Neuartige formulierungen zur behandlung von migräne
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) * 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
CA2730340C (en) * 2008-07-14 2017-02-07 Polypid Ltd. Sustained-release drug carrier composition
MX352189B (es) 2008-09-04 2017-11-10 Amylin Pharmaceuticals Llc Formulaciones de liberación sostenida usando portadores no acuosos.
EA016540B1 (ru) * 2008-12-30 2012-05-30 Ооо "Научно-Производственный Комплекс "Наносистема" Фармацевтическая композиция для лечения туберкулеза, способ ее получения и способ лечения туберкулеза
US20100239632A1 (en) * 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
CN102470105B (zh) 2009-07-14 2015-07-29 波利皮得有限公司 持续释放药物载体组合物
WO2011035013A2 (en) * 2009-09-17 2011-03-24 Surmodics Pharmaceuticals, Inc. Implant devices that differ by release profile and methods of making and using same
KR101823699B1 (ko) 2009-09-28 2018-01-30 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
AU2011208374B2 (en) * 2010-01-19 2016-09-08 Polypid Ltd. Sustained-release nucleic acid matrix compositions
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
JP6045575B2 (ja) 2011-06-23 2016-12-14 ディーエスエム アイピー アセッツ ビー．ブイ． 薬物送達のための新規な生分解性ポリエステルアミドコポリマー
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
US8716363B2 (en) * 2011-09-28 2014-05-06 Globus Medical, Inc. Biodegradable putty compositions and implant devices, methods, and kits relating to the same
EP2841098A4 (de) 2012-04-23 2016-03-02 Allertein Therapeutics Llc Nanopartikel zur behandlung von allergien
CA2871821C (en) 2012-05-10 2021-01-12 Painreform Ltd. Depot formulations of a local anesthetic and methods for preparation thereof
EA027543B1 (ru) * 2012-08-02 2017-08-31 Полипид Лтд. Композиции и способы для лечения участков отсутствующей костной ткани и открытых переломов
JP2016516754A (ja) 2013-04-03 2016-06-09 アラーテイン・セラピューティクス・リミテッド・ライアビリティ・カンパニーＡｌｌｅｒｔｅｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ 新規のナノ粒子組成物
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
DE112015005320T5 (de) * 2014-11-25 2017-08-31 Cbc Co., Ltd. Janus Nanopartikel und Verfahren zur Herstellung derselben
JP6720447B2 (ja) 2014-12-18 2020-07-08 ディーエスエム アイピー アセッツ ビー．ブイ．Ｄｓｍ Ｉｐ Ａｓｓｅｔｓ Ｂ．Ｖ． 酸感受性薬剤の送達のための薬剤送達系
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
AU2017268161B2 (en) 2016-05-16 2020-03-12 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
IL307966A (en) 2017-01-03 2023-12-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
WO2018140856A1 (en) * 2017-01-30 2018-08-02 Bio-Rad Laboratories, Inc. Emulsion compositions and methods of their use
RU2697411C2 (ru) * 2017-10-11 2019-08-14 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Композиция для лечения болезни Паркинсона
EP3701943A1 (de) * 2019-02-26 2020-09-02 CAPNOMED GmbH Verzögerte abgabe von antikrebsmitteln
CA3153224A1 (en) * 2019-09-19 2021-03-25 Amw Gmbh Extruded depot form for controlled active substance release
JP7518627B2 (ja) 2020-02-05 2024-07-18 京セラ株式会社 薬剤徐放性組成物
US11992483B2 (en) 2021-03-31 2024-05-28 Cali Biosciences Us, Llc Emulsions for local anesthetics
KR20230115591A (ko) * 2022-01-27 2023-08-03 주식회사 티온랩테라퓨틱스 초기 방출 제어된 지질 융합 데포 조성물 및 이의 제조방법

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US305158A (en) 1884-09-16 devore
US723583A (en) 1902-12-13 1903-03-24 Ephraim Chabot Adjustable shade-roller holder.
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US5186941A (en) 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
US4622219A (en) 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4599342A (en) 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4744989A (en) 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
US5141674A (en) 1984-03-08 1992-08-25 Phares Pharmaceutical Research N.V. Methods of preparing pro-liposome dispersions and aerosols
DE3585967D1 (de) 1984-03-08 1992-06-11 Phares Pharma Holland Liposombildende zusammensetzung.
US4610868A (en) 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4761288A (en) 1984-09-24 1988-08-02 Mezei Associates Limited Multiphase liposomal drug delivery system
ES2039203T3 (es) 1985-11-22 1993-09-16 Takeda Chemical Industries, Ltd. Composicion de liposomas.
US5244678A (en) 1986-01-14 1993-09-14 Ire-Celltarg S.A. Pharmaceutical composition containing a local anesthetic and/or centrally acting analgesic encapsulated in liposomes
JPH0751496B2 (ja) 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
ES2032776T3 (es) 1986-05-20 1993-03-01 Wako Pure Chemical Industries, Ltd. Nuevos liposomas funcionalizados y un procedimiento para su produccion.
US4877619A (en) 1986-08-25 1989-10-31 Vestar, Inc. Liposomal vesicles for intraperitoneal administration of therapeutic agents
US5723147A (en) 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
DK86988A (da) 1987-02-25 1988-08-26 Takeda Chemical Industries Ltd Liposompraeparat og anvendelse deraf
JP2666345B2 (ja) 1987-04-16 1997-10-22 武田薬品工業株式会社 リポソーム製剤およびその製造法
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
JP2727326B2 (ja) * 1988-08-03 1998-03-11 ライオン株式会社 温度感応性微小球体
US4937078A (en) 1988-08-26 1990-06-26 Mezei Associates Limited Liposomal local anesthetic and analgesic products
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5049392A (en) 1989-01-18 1991-09-17 The Liposome Company, Inc. Osmotically dependent vesicles
US5364632A (en) 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5227165A (en) 1989-11-13 1993-07-13 Nova Pharmaceutical Corporation Liposphere delivery systems for local anesthetics
EP0502119B1 (de) * 1989-11-13 1996-01-31 Scios Nova, Inc. Liposphären zur kontrollierten substanzabgabe
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
IS1685B (is) 1990-12-11 1998-02-24 Bracco International B.V. Aðferð við að búa til fitukúlur (liposomes) sem eru gæddar auknum hæfileika til að draga í sig og halda í sér aðskotaefnum
US5977326A (en) 1991-08-06 1999-11-02 Salford Ultrafine Chemicals And Research Limited Process for making morphine-6-glucuronide or substituted morphine-6-glucuronide
SE9200952D0 (sv) 1992-03-27 1992-03-27 Kabi Pharmacia Ab Pharmaceutical carrier system containing defined lipids
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
JPH06247842A (ja) 1993-02-23 1994-09-06 Green Cross Corp:The リポソーム組成物の製造方法
US5891842A (en) 1993-04-09 1999-04-06 Trustees Of Tufts College Methodology for eliciting an analgesic response in a living subject
US5455044A (en) 1993-05-14 1995-10-03 Depotech Corporation Method for treating neurological disorders
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5853755A (en) 1993-07-28 1998-12-29 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles
GB9320668D0 (en) 1993-10-07 1993-11-24 Secr Defence Liposomes containing particulare materials
US5849763A (en) 1993-10-13 1998-12-15 Darwin Discovery Limited Use of levobupivacaine as an anesthetic agent
WO1995010277A1 (en) 1993-10-13 1995-04-20 Chiroscience Limited Analgesic agent and its use
GB9321061D0 (en) 1993-10-13 1993-12-01 Chiroscience Ltd Analgestic agent and its use
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
US5451408A (en) 1994-03-23 1995-09-19 Liposome Pain Management, Ltd. Pain management with liposome-encapsulated analgesic drugs
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6048545A (en) 1994-06-24 2000-04-11 Biozone Laboratories, Inc. Liposomal delivery by iontophoresis
US6066331A (en) 1994-07-08 2000-05-23 Barenholz; Yechezkel Method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers
SE9402453D0 (sv) 1994-07-12 1994-07-12 Astra Ab New pharmaceutical preparation
DE4430592A1 (de) 1994-08-20 1996-02-22 Max Delbrueck Centrum Liposomale Zubereitung, ihre Herstellung und ihre Verwendung
US5993850A (en) * 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
US5702722A (en) 1994-09-30 1997-12-30 Bracco Research S.A. Liposomes with enhanced entrapment capacity, method and use
JPH10513471A (ja) 1995-02-10 1998-12-22 メドトロニック、インコーポレイテッド 鎮痛薬投与のための方法と装置
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
JP3191004B2 (ja) * 1995-12-15 2001-07-23 武田薬品工業株式会社 マイクロスフェアの製造法
GB9605915D0 (en) 1996-03-21 1996-05-22 Univ Bruxelles Liposome encapsulated amphiphilic drug compositions
US5808573A (en) 1996-08-01 1998-09-15 Nec Electronics Incorporated Methods and structure for sampled-data timing recovery with reduced complexity and latency
AU3981097A (en) * 1996-08-21 1998-03-06 Alkermes Controlled Therapeutics, Inc. Controlled release microparticles with a hydrophobic material
US6046187A (en) 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
ES2321769T3 (es) 1996-10-15 2009-06-10 Transave, Inc. Liposomas de n-acil fosfatidiletanolamina para el transporte de medicamentos.
WO1998024415A1 (en) 1996-12-02 1998-06-11 The Regents Of The University Of California A bilayer structure which encapsulates multiple containment units and uses thereof
US5767627A (en) 1997-01-09 1998-06-16 Trusi Technologies, Llc Plasma generation and plasma processing of materials
US5865184A (en) 1997-01-13 1999-02-02 Takiguchi; Tetsuo Combined spinal and epidural anesthesia
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
GB9704351D0 (en) 1997-03-03 1997-04-23 Chiroscience Ltd Levobupivacaine and its use
GB9704352D0 (en) 1997-03-03 1997-04-23 Chiroscience Ltd Levobupivacaine and its use
EP1201241B8 (de) 1997-03-13 2010-10-27 James N. Campbell Zusammensetzungen enthaltend Capsaicin oder Capsaicin Analoge und ein Anästhetikum
US6020004A (en) * 1997-04-17 2000-02-01 Amgen Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
JP2000511941A (ja) 1997-07-02 2000-09-12 ユーロ−セルティーク エス．エイ． 関節間隙および身体間隙における持効性麻酔
US6287587B2 (en) 1997-07-15 2001-09-11 Takeda Chemical Industries, Ltd. Process for producing sustained-release preparation by in-water drying
WO1999004771A2 (en) 1997-07-21 1999-02-04 Darwin Discovery Limited Use of levobupivacaine
US6432986B2 (en) 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US20010004644A1 (en) 1997-07-21 2001-06-21 Levin Bruce H. Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation
PT998287E (pt) 1997-07-22 2003-09-30 Darwin Discovery Ltd Utilizacao de levobupivacaina
US6423345B2 (en) * 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
FR2932229B1 (fr) 2008-06-05 2011-06-24 Renault Sas Pilotage de l'alimentation electrique d'une bougie d'allumage d'un moteur a combustion interne
US8683976B2 (en) 2011-02-16 2014-04-01 Ford Global Technologies, Llc Spark plug degradation detection
ES2461969T3 (es) 2011-03-22 2014-05-21 Agie Charmilles Sa Procedimiento y dispositivo para la transmisión digital de datos

Also Published As

Publication number Publication date
NZ509186A (en) 2005-01-28
CA2338031A1 (en) 2000-01-27
US20010048945A1 (en) 2001-12-06
US6793938B2 (en) 2004-09-21
IL140899A0 (en) 2002-02-10
ATE428371T1 (de) 2009-05-15
CA2338031C (en) 2006-12-05
WO2000003660A1 (en) 2000-01-27
NO20010264D0 (no) 2001-01-16
IL140899A (en) 2007-05-15
EP1098610B1 (de) 2009-04-15
AU5003099A (en) 2000-02-07
US6277413B1 (en) 2001-08-21
AU752225B2 (en) 2002-09-12
JP2011063596A (ja) 2011-03-31
JP2002520120A (ja) 2002-07-09
EP1098610A1 (de) 2001-05-16
EP1098610A4 (de) 2003-09-03
ES2325141T3 (es) 2009-08-26
NO20010264L (no) 2001-03-06

Similar Documents

Publication Publication Date Title
DE69940735D1 (de) Biologisch abbaubare anordnungen zur kontrollierten freigabe eingeschlossener substanzen
Chen et al. Enhancement of periodontal tissue regeneration by locally controlled delivery of insulin-like growth factor-I from dextran–co-gelatin microspheres
US4855134A (en) Sustained-release preparation
BR9405798A (pt) Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
ATE464885T1 (de) Verfahern zur herstellung von festen verabreichungssystemen für eingekapselte und nicht-eingekapselte pharmazeutische wirkstoffe
NZ501950A (en) Medicinal compositions for application to mucosa
DE59908745D1 (de) Pharmazeutische ciclosporin-formulierung mit verbesserten biopharmazeutischen eigenschaften, erhöhter physikalischer qualität & stabilität sowie verfahren zur herstellung
Dong et al. Injectable adhesive hydrogel through a microcapsule cross-link for periodontitis treatment
ATE249422T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
WO2003099225A3 (en) Compositions for delivering nucleic acids to cells
EP0138216B1 (de) IFN-Präparat mit verzögerter Abgabe für parentale Verabreichung
ATE206041T1 (de) Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe
ATE202926T1 (de) Pharmazeutische brausepräparate enthaltend bioabbaubare mikrokapseln zur kontrolierten wirkstofffreisetzung
JPS60231609A (ja) リポソ−ム製剤
Chien et al. Transdermal controlled administration of indomethacin. I. Enhancement of skin permeability
NO20092662L (no) Sammensetning med forlenget frigjoring og fremgangsmate for a produsere det samme
SE9704401D0 (sv) Matrix pellets for greasy, oily or sticky drug substances
Graham et al. Polymeric inserts and implants for the controlled release of drugs
DZ3473A1 (fr) Formulation pharmaceutique a liberation prolongee independante de la force ionique.
HRP20080178T3 (en) Pharmaceutical composition in the form of a hydrogel for transdermal administration of active substances
JP2019523302A (ja) 腋臭を治療する方法
SE9704400D0 (sv) Porous inorganic particles as carriers for drug substances
Sax et al. In-vivo biodegradation of extruded lipid implants in rabbits
DE60111637D1 (de) Biomaterial in form von mikropartikeln von hyaluronsaure zur medizinischen verwendung
AU2931200A (en) Delivery of microparticle formulations using needleless syringe device for sustained-release of bioactive compounds

Legal Events

Date Code Title Description
8364 No opposition during term of opposition